Jonathan Zalevsky
Chief R&D Officer at Nektar Therapeutics (NKTR)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $974K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 20SEC | NKTRNektar Therapeutics | Sell | 1869,570 held (−2%) | $71.98 | $13K | -42.8% |
| Jul 2SEC | NKTRNektar Therapeutics | Sell Plan | 5,6819,756 held (−37%) | $70.00 | $398K | -41.2% |
| Jun 17SEC | NKTRNektar Therapeutics | Sell Plan | 5,53815,437 held (−26%) | $60.71 | $336K | -32.2% |
| May 21SEC | NKTRNektar Therapeutics | Sell | 19920,975 held (−1%) | $65.51 | $13K | -37.2% |
| Feb 20SEC | NKTRNektar Therapeutics | Sell | 18021,174 held (−1%) | $73.00 | $13K | -43.6% |
| Jan 22SEC | NKTRNektar Therapeutics | Sell Plan | 3,86721,354 held (−15%) | $35.67 | $138K | +15.4% |
| Nov 25SEC | NKTRNektar Therapeutics | Sell | 1,15718,971 held (−6%) | $54.28 | $63K | -24.2% |
- Sell
Chief R&D Officer Jonathan Zalevsky sold $398K of NKTR at $70.00 — cuts the stake by 37%; pre-scheduled 10b5-1 plan sale.
- Sell
Chief R&D Officer Jonathan Zalevsky sold $336K of NKTR at $60.71 — cuts the stake by 26%; pre-scheduled 10b5-1 plan sale.
- Sell
Chief R&D Officer Jonathan Zalevsky sold $138K of NKTR at $35.67 — pre-scheduled 10b5-1 plan sale.